Analysts’ Recent Ratings Updates for AtriCure (ATRC)

A number of research firms have changed their ratings and price targets for AtriCure (NASDAQ: ATRC):

• 11/4/2026 – AtriCure had its price target raised by BTIG Research from $63.00 to $70.00. They now have a “buy” rating on the stock.
• 11/4/2026 – AtriCure was upgraded by Zacks Research from “hold” to “strong-buy”.
• 11/4/2026 – AtriCure had its price target raised by Canaccord Genuity Group from $55.00 to $67.00. They now have a “buy” rating on the stock.
• 11/4/2026 – AtriCure had its price target raised by JPMorgan Chase & Co. from $36.00 to $62.00. They now have a “neutral” rating on the stock.
• 11/4/2026 – AtriCure had its “overweight” rating reaffirmed by Piper Sandler. They now have a $70.00 price target on the stock, up from $60.00.
• 11/4/2026 – AtriCure had its price target raised by Needham & Company LLC from $64.00 to $70.00. They now have a “buy” rating on the stock.
• 10/21/2026 – AtriCure had its “market outperform” rating reaffirmed by Citigroup.
• 10/21/2026 – AtriCure was downgraded by UBS Group from “buy” to “sell”.
• 10/21/2026 – AtriCure had its price target raised by Citizens Jmp from $52.00 to $68.00. They now have a “market outperform” rating on the stock.
• 10/12/2026 – AtriCure had its price target raised by BTIG Research from $55.00 to $63.00. They now have a “buy” rating on the stock.
• 10/8/2026 – AtriCure was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 10/2/2026 – AtriCure was downgraded by Freedom Capital from “strong-buy” to “hold”.
• 9/17/2026 – AtriCure was given a new $65.00 price target by Stifel Nicolaus.

AtriCure Stock Performance

ATRC stock traded down $2.74 during midday trading on Friday, reaching $58.54. The company had a trading volume of 614,651 shares, compared to its average volume of 873,971. The firm has a market capitalization of $2.98 billion, a PE ratio of 195.14 and a beta of 1.23. The stock has a 50 day moving average price of $56.81 and a 200 day moving average price of $38.73. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $66.02. The company has a quick ratio of 3.19, a current ratio of 4.33 and a debt-to-equity ratio of 0.11.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.23. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. The business had revenue of $154.45 million for the quarter, compared to analysts’ expectations of $151.05 million. Analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other AtriCure news, Director Regina E. Groves sold 5,313 shares of the business’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $54.22, for a total transaction of $288,070.86. Following the completion of the transaction, the director owned 34,546 shares in the company, valued at approximately $1,873,084.12. The trade was a 13.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Karl S. Dahlquist sold 9,370 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares of the company’s stock, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 39,026 shares of company stock valued at $2,172,263 in the last three months. 4.00% of the stock is currently owned by corporate insiders.

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.